Stockreport

Nektar Therapeutics: Rezpeg's Phase 2b Alopecia Areata Results Leave Many Questions [Seeking Alpha]

Nektar Therapeutics  (NKTR) 
Last nektar therapeutics earnings: 2/27 04:15 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.nektar.com/investor-relations
PDF Rezpeg demonstrated modest efficacy and good safety in AtD Phase 2b but faces stiff competition from established biologics like Dupixent. Phase 2b AA results for the [Read more]